These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
121 related articles for article (PubMed ID: 19586829)
41. Metallothionein isoform II expression in hyperplastic, dysplastic and neoplastic prostatic lesions. El Sharkawy SL; Abbas NF; Badawi MA; El Shaer MA J Clin Pathol; 2006 Nov; 59(11):1171-4. PubMed ID: 16574721 [TBL] [Abstract][Full Text] [Related]
42. Hyaluronan-mediated motility receptor (RHAMM) immunohistochemical expression and androgen deprivation in normal peritumoral, hyperplasic and neoplastic prostate tissue. Korkes F; de Castro MG; de Cassio Zequi S; Nardi L; Del Giglio A; de Lima Pompeo AC BJU Int; 2014 May; 113(5):822-9. PubMed ID: 24053431 [TBL] [Abstract][Full Text] [Related]
43. Oncogenic transformation of human benign prostate hyperplasia with chronic cadmium exposure. Prajapati A; Chauhan G; Shah H; Gupta S J Trace Elem Med Biol; 2020 Dec; 62():126633. PubMed ID: 32818862 [TBL] [Abstract][Full Text] [Related]
44. Effects of cadmium on metallothionein-I and metallothionein-II mRNA expression in rat ventral, lateral, and dorsal prostatic lobes: quantification by competitive RT-PCR. Lee KF; Lau KM; Ho SM Toxicol Appl Pharmacol; 1999 Jan; 154(1):20-7. PubMed ID: 9882588 [TBL] [Abstract][Full Text] [Related]
45. Expression of survivin and apoptotic biomarkers in benign prostatic hyperplasia. Shariat SF; Ashfaq R; Roehrborn CG; Slawin KM; Lotan Y J Urol; 2005 Nov; 174(5):2046-50. PubMed ID: 16217391 [TBL] [Abstract][Full Text] [Related]
46. Tissue and serum levels of principal androgens in benign prostatic hyperplasia and prostate cancer. Heracek J; Hampl R; Hill M; Starka L; Sachova J; Kuncova J; Eis V; Urban M; Mandys V Steroids; 2007 Apr; 72(4):375-80. PubMed ID: 17368496 [TBL] [Abstract][Full Text] [Related]
47. Immunohistochemical study of the expression of epidermal growth factor receptor in benign prostatic hypertrophy, prostatic intraepithelial neoplasia and prostatic carcinoma. Rana S; Sen R; Kalra R; Arora B; Sharma P; Gahlawat S Indian J Pathol Microbiol; 2006 Oct; 49(4):495-9. PubMed ID: 17183836 [TBL] [Abstract][Full Text] [Related]
48. Comparative study of concentration of isoflavones and lignans in plasma and prostatic tissues of normal control and benign prostatic hyperplasia. Hong SJ; Kim SI; Kwon SM; Lee JR; Chung BC Yonsei Med J; 2002 Apr; 43(2):236-41. PubMed ID: 11971218 [TBL] [Abstract][Full Text] [Related]
49. Variation of metal and metallothionein concentrations in a natural population of Ruditapes decussatus. Bebianno MJ; Serafim MA Arch Environ Contam Toxicol; 2003 Jan; 44(1):53-66. PubMed ID: 12434219 [TBL] [Abstract][Full Text] [Related]
50. [Analysis of the differences in the expression of HSP27 and c-kit between benign prostatic hyperplasia and prostatic cancer tissues]. Zhen B; Shen Y; Zhang YM; Zhu CH; Liu ZL Zhonghua Nan Ke Xue; 2006 May; 12(5):416-20. PubMed ID: 16755871 [TBL] [Abstract][Full Text] [Related]
51. Induction and binding of Cd, Cu, and Zn to metallothionein in carp (Cyprinus carpio) using HPLC-ICP-TOFMS. Van Campenhout K; Infante HG; Adams F; Blust R Toxicol Sci; 2004 Aug; 80(2):276-87. PubMed ID: 15103052 [TBL] [Abstract][Full Text] [Related]
52. Microvessel density as a molecular marker for identifying high-grade prostatic intraepithelial neoplasia precursors to prostate cancer. Sinha AA; Quast BJ; Reddy PK; Lall V; Wilson MJ; Qian J; Bostwick DG Exp Mol Pathol; 2004 Oct; 77(2):153-9. PubMed ID: 15351240 [TBL] [Abstract][Full Text] [Related]
53. Induction of metallothionein synthesis in cultured human trophoblasts by cadmium and zinc. Lehman LD; Poisner AM J Toxicol Environ Health; 1984; 14(2-3):419-32. PubMed ID: 6502743 [TBL] [Abstract][Full Text] [Related]
54. Feasibility of holmium laser enucleation of the prostate (HoLEP) for recurrent/residual benign prostatic hyperplasia (BPH). Elshal AM; Elmansy HM; Elhilali MM BJU Int; 2012 Dec; 110(11 Pt C):E845-50. PubMed ID: 22702908 [TBL] [Abstract][Full Text] [Related]
55. Prevalence of histological prostatitis in men with benign prostatic hyperplasia or adenocarcinoma of the prostate presenting without urinary retention. Edlin RS; Heyns CF; Van Vuuren SP; Zarrabi AD S Afr J Surg; 2012 Nov; 50(4):127-30. PubMed ID: 23217554 [TBL] [Abstract][Full Text] [Related]
57. Accumulation of p53 and expression of CD44 in human prostatic cancer and benign prostatic hyperplasia: an immunohistochemical study. Zhang XH; Sakamoto H; Takenaka I Br J Urol; 1996 Mar; 77(3):441-4. PubMed ID: 8814853 [TBL] [Abstract][Full Text] [Related]
58. Immunohistochemistry of the androgen receptor in human benign and malignant prostate tissue. Miyamoto KK; McSherry SA; Dent GA; Sar M; Wilson EM; French FS; Sharief Y; Mohler JL J Urol; 1993 May; 149(5):1015-9. PubMed ID: 7683339 [TBL] [Abstract][Full Text] [Related]
59. A single low dose of cadmium exposure induces benign prostate hyperplasia like condition in rat: A novel benign prostate hyperplasia rodent model. Prajapati A; Rao A; Patel J; Gupta S; Gupta S Exp Biol Med (Maywood); 2014 Jul; 239(7):829-841. PubMed ID: 24872436 [TBL] [Abstract][Full Text] [Related]
60. Integrative exploration of the mutual gene signatures and immune microenvironment between benign prostate hyperplasia and castration-resistant prostate cancer. Wu F; Ning H; Sun Y; Wu H; Lyu J Aging Male; 2023 Dec; 26(1):2183947. PubMed ID: 36974949 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]